Share class: ImmuCell Corporation

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A19,105,6226,141,628 ( 67.45 %) 58,823 ( 0.646 %) 67.45 %

Major shareholders: ImmuCell Corporation

NameStocks%Valuation
9.205 %
832,790 9.205 % 9 M $
7.119 %
644,019 7.119 % 7 M $
5.682 %
514,003 5.682 % 5 M $
5.552 %
502,258 5.552 % 5 M $
4.442 %
401,819 4.442 % 4 M $
Vanguard Capital Management LLC
2.878 %
260,327 2.878 % 3 M $
Morgan Stanley Smith Barney LLC
2.451 %
221,716 2.451 % 2 M $
2.395 %
216,700 2.395 % 2 M $
Renaissance Technologies LLC
1.678 %
151,789 1.678 % 2 M $
1.513 %
136,882 1.513 % 1 M $
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Individuals37.68%
Institutional14.02%
Others1.11%
Unknown47.19%

Based on 1000 largest holdings

Geographical origin of shareholders

Individuals
37.68%
United States
14.05%
Australia
0.56%
United Kingdom
0.46%
Ireland
0.06%

Based on 1000 largest holdings

Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!